Arcus Biosciences
Arcus Biosciences, a clinical-stage biopharmaceutical company, develops novel cancer therapies using emerging immunology insights, with four molecules in clinical development.
Founded
2015Arcus Biosciences, a clinical-stage biopharmaceutical company, develops novel cancer therapies using emerging immunology insights, with four molecules in clinical development.
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies. The company leverages emerging insights in immunology to design combination therapies with best-in-class potential. Arcus's primary mission is to discover, develop, and commercialize novel treatments for various types of cancer, aiming to create more effective therapeutic options for patients.
The company has made significant progress in its clinical development pipeline, with four molecules currently undergoing clinical trials. One of their notable candidates is Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist to enter clinical trials. Arcus is actively evaluating this compound, along with other potential therapies, in multiple Phase 2 and 1b studies across different indications, demonstrating their commitment to advancing cancer treatment options.
Companies similar to Arcus Biosciences include Arcutis Biotherapeutics, Precision BioSciences, Arc Bio and Kronos Bio.
Arcus Biosciences was founded in 2015.
Arcus Biosciences' headquarters is located in Hayward, CA, US.
Arcus Biosciences' most recent funding round was for $320M (USD) in January 2024.
As of Jan 29, 2024, Arcus Biosciences has disclosed funding of $967M (USD). Undisclosed round amounts are excluded.
Arcus Biosciences has 550 employees as of Feb 6, 2024.
Kronos Bio
kronosbio.com
